Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts on obeticholic acid (OCA), including a late-breaking oral presentation of long-term data in primary biliary cholangitis (PBC), will be presented at The Liver Meeting 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting will be held virtually from November 12 to November 15, 2021.
“The Global PBC and UK-PBC databases have provided researchers with a wealth of information about the natural history of PBC, and this late-breaking presentation at The Liver Meeting will apply those learnings to help us understand OCA’s potential to improve liver transplant-free survival,” said M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept. “We are thankful to all of the patients who have contributed their data to the Global PBC and UK-PBC study groups, and we also thank the team of international researchers who collaborated on this groundbreaking study.”
“The Liver Meeting will also feature two Intercept poster presentations with important implications for the NASH field,” continued Dr. Berrey. “The first describes a new consensus panel methodology for assessing liver biopsies that we believe can help improve the accuracy of histological scoring in NASH clinical trials. The second provides an overview of the REVERSE study design and baseline characteristics of enrolled patients with compensated cirrhosis due to NASH. REVERSE is the next major Phase 3 trial readout in NASH and will help us determine if OCA can benefit this more advanced patient population with very high unmet need.”
The use of OCA for fibrosis due to NASH is investigational and has not been approved by the U.S. Food and Drug Administration, the European Commission or any other health authority.